Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03108131 · FLOW

Participant flow

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors · Source last updated 2025-05-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Must be refractory or intolerant to at least one line of 5FU-based chemotherapy for metastatic disease and must not have clinically symptomatic malignant small bowel obstruction. Cobimetinib (60 mgorally once daily for days 1 - 21) and atezolizumab (840 mg intravenously every 2 weeks) every 28-day cycle.
    id
    FG000
    title
    Small Bowel Adenocarcinoma
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        20
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        20
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Out of the 49 patients that was enrolled at MD Anderson Cancer Center Houston, Tx, only 20 patients had Small Bowel Adenocarcinoma. The rest had other solid tumors and their data was not used in the analysis for the group of patients with Small Bowel Adenocarcinoma.
Complete source fields
groups
  1. description
    Must be refractory or intolerant to at least one line of 5FU-based chemotherapy for metastatic disease and must not have clinically symptomatic malignant small bowel obstruction. Cobimetinib (60 mgorally once daily for days 1 - 21) and atezolizumab (840 mg intravenously every 2 weeks) every 28-day cycle.
    id
    FG000
    title
    Small Bowel Adenocarcinoma
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        20
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        20
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Out of the 49 patients that was enrolled at MD Anderson Cancer Center Houston, Tx, only 20 patients had Small Bowel Adenocarcinoma. The rest had other solid tumors and their data was not used in the analysis for the group of patients with Small Bowel Adenocarcinoma.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice